BNT329
/ BioNTech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
December 04, 2025
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
(clinicaltrials.gov)
- P1/2 | N=245 | Recruiting | Sponsor: BioNTech SE | Not yet recruiting ➔ Recruiting
Enrollment open • First-in-human • Oncology • Solid Tumor • CA 19-9
September 23, 2025
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
(clinicaltrials.gov)
- P1/2 | N=245 | Not yet recruiting | Sponsor: BioNTech SE
First-in-human • New P1/2 trial • Oncology • Solid Tumor • CA 19-9
1 to 2
Of
2
Go to page
1